TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21339418

Group type: EXPERIMENTAL
Intervention: Educational workbook
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual care with a nephrologist
Number of subjects: 75
Study: 19155896

Group type: EXPERIMENTAL
Intervention: 17 alpha‐hydroxyprogesterone caproate (250 mg, weekly intramuscular injections starting at 16-20 weeks until delivery or 35 weeks)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Placebo (matching injections, same schedule as intervention)
Number of subjects: 134
Study: 17573388

Group type: EXPERIMENTAL
Intervention: Sham pressure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cricoid pressure (for laryngeal tube)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cricoid pressure (for laryngeal tube-suction II)
Number of subjects: 40
Study: 14767244

Group type: EXPERIMENTAL
Intervention: Trained subjects (60%GET)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trained subjects (80%GET)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Trained subjects (50%Delta)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Untrained subjects (60%GET)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Untrained subjects (80%GET)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Untrained subjects (50%Delta)
Number of subjects: 15
Study: 15567936

Group type: EXPERIMENTAL
Intervention: Single-agent docetaxel (T)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Single-agent doxorubicin (A)
Number of subjects: 326
Study: 10394163

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control Group (noncardiac patients under GA)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control Group (cardiac patients under GA)
Number of subjects: 107
Study: 7747861

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 40
Study: 2202445

Group type: EXPERIMENTAL
Intervention: Structured behavioural change programme
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: Simple advice programme
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 311
Study: 6788275

Group type: EXPERIMENTAL
Intervention: Naftidrofuryl infusion
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study: 30797266

Group type: EXPERIMENTAL
Intervention: ATT with cholecalciferol (Group-B)
Number of subjects: 496

Group type: COMPARATOR
Intervention: ATT (Group-A)
Number of subjects: 496
Study: 28852819

Group type: COMPARATOR
Intervention: −20° < AHP < 0° group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 20° > AHP > 0° group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 40° > AHP > 20° group
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 54
Study: 27072947

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation group (experimental intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham meditation group (active control)
Number of subjects: 60
Study: 24412801

Group type: COMPARATOR
Intervention: 50 mg DKP
Number of subjects: 93

Group type: COMPARATOR
Intervention: 25 mg DKP
Number of subjects: 93
Study: 22333955

Group type: EXPERIMENTAL
Intervention: Classification-based treatment approach
Number of subjects: 156

Group type: COMPARATOR
Intervention: Usual physical therapy care
Number of subjects: 156
Study: 18702848

Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Tocotrienol-rich fraction (TRF)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17071953

Group type: EXPERIMENTAL
Intervention: Pedimune Baby
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Pedimune Junior
Number of subjects: 6

Group type: COMPARATOR
Intervention: Branded drugs
Number of subjects: 6
Study: 14687051

Group type: EXPERIMENTAL
Intervention: Misoprostol (25 mcg, hospital-prepared capsule)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 681

Group type: COMPARATOR
Intervention: Dinoprostone (1 mg gel)
Number of subjects: 681

Group type: COMPARATOR
Intervention: Dinoprostone
Number of subjects: 681
Study: 12117483

Group type: EXPERIMENTAL
Intervention: 30% of maximum inspiratory pressure (P(imax))
Number of subjects: 16

Group type: COMPARATOR
Intervention: Less than 5% of maximum inspiratory pressure (P(imax))
Number of subjects: 16
Study: 10723516

Group type: EXPERIMENTAL
Intervention: Stavudine-based multiple agent combinations (including protease inhibitor-containing and -sparing regimens, triple nucleoside RTI regimens, and regimens including non-nucleoside RTIs and/or hydroxyurea)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stavudine-based multiple agent combinations
Number of subjects: 0
Study: 7712309

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU three times per week for 6 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU daily for 6 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (5 MU three times per week or daily for 6 months)
Number of subjects: 31
Study: 31843266

Group type: EXPERIMENTAL
Intervention: SIIPL-PCV
Number of subjects: 346

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 346
Study: 31178940

Group type: EXPERIMENTAL
Intervention: High medication necessity belief
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: High concern belief about potential adverse effects
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Negative belief toward medications
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Seizure encounter within the last 3 months
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Low medication necessity belief
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: High medication concern belief
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Negative medication belief
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Nonadherence to medications
Number of subjects: 292
Study: 28728854

Group type: EXPERIMENTAL
Intervention: BI-RADS Mammography Atlas 5th Edition for reporting and assessing lesions on DBCT
Number of subjects: 4
Study: 26565077

Group type: EXPERIMENTAL
Intervention: Dalfampridine ER 10 mg BID
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Dalfampridine ER 5 mg BID
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 23563245

Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (1.7 g DHA and 0.6 g EPA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 20431530

Group type: EXPERIMENTAL
Intervention: Losartan-based antihypertensive treatment
Number of subjects: 7489

Group type: COMPARATOR
Intervention: Atenolol-based antihypertensive treatment
Number of subjects: 7489

Group type: EXPERIMENTAL
Intervention: Baseline quartiles of SUA
Number of subjects: 7489

Group type: EXPERIMENTAL
Intervention: Time-varying SUA
Number of subjects: 7489
Study: 17956497

Group type: EXPERIMENTAL
Intervention: 250 mg sulphadoxine/2.5 mg pyrimethamine
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 15757762

Group type: EXPERIMENTAL
Intervention: Closed reduction and transarticular Kirschner wire fixation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Open reduction and internal fixation (one or two lag screws or cerclage wire)
Number of subjects: 19
Study: 12192104

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9973898

Group type: EXPERIMENTAL
Intervention: Bilateral phlebography
Number of subjects: 1827
Study: 7754939

Group type: EXPERIMENTAL
Intervention: Enalapril treatment initiated < 24 hours after AMI
Number of subjects: 428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 428
Study: 2279540

Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon at 3 MU/day over 3 months and then 3 MU/three times/week over 9 months
Number of subjects: 107

Group type: COMPARATOR
Intervention: no further treatment (control group)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: alpha‐2b interferon
Number of subjects: 107
Study: 6793924

Group type: EXPERIMENTAL
Intervention: Acetylsalicylate of lysine (1.8 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetylsalicylate of lysine (3.6 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocine (30 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pentazocine (60 mg)
Number of subjects: 40
Study: 30347587

Group type: EXPERIMENTAL
Intervention: Unipedicular approach
Number of subjects: 382

Group type: COMPARATOR
Intervention: Bipedicular approach
Number of subjects: 382
Study: 27841694

Group type: EXPERIMENTAL
Intervention: Voice rehabilitation post-radiotherapy
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no voice rehabilitation)
Number of subjects: 65
Study: 26303134

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 μg BID for 8 weeks
Number of subjects: 15
Study: 23525738

Group type: EXPERIMENTAL
Intervention: High-dose sevoflurane (1.5 MAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Moderate-dose sevoflurane (1.0 MAC)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose sevoflurane (0.5 MAC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No sevoflurane (control)
Number of subjects: 120
Study: 21488754

Group type: EXPERIMENTAL
Intervention: 30 g of English walnuts per day for 30 days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 30 g of black walnuts per day for 30 days
Number of subjects: 36
Study: 19716560

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1829
Study: 17671215

Group type: EXPERIMENTAL
Intervention: zoledronate + IL-2
Number of subjects: 18

Group type: COMPARATOR
Intervention: zoledronate
Number of subjects: 18
Study: 15923688

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention delivered monthly by trained counsellors
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention
Number of subjects: 138

Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 138
Study: 11973440

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 mg daily
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 5 mg daily
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 10 mg daily
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 20 mg daily
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Oral 17beta-estradiol 1 mg daily continuously combined with dydrogesterone 2.5 to 20 mg daily
Number of subjects: 508
Study: 9819446

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 24 weeks
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Combination therapy with interferon alfa-2b and ribavirin (1000 or 1200 mg orally per day) for 48 weeks
Number of subjects: 912

Group type: COMPARATOR
Intervention: Interferon alfa-2b alone for 24 weeks
Number of subjects: 912

Group type: COMPARATOR
Intervention: Interferon alfa-2b alone for 48 weeks
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Combination therapy for 24 weeks
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Combination therapy for 48 weeks
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 912
Study: 7657738

Group type: EXPERIMENTAL
Intervention: Pergonal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Humegon
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pergonal batches
Number of subjects: 20
Study: 2711343

Group type: EXPERIMENTAL
Intervention: p(60) + Be-neutrons
Number of subjects: 67

Group type: COMPARATOR
Intervention: photons
Number of subjects: 67
Study: 8961

Group type: EXPERIMENTAL
Intervention: Single intracarotid injection of phenoxybenzamine
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Prolonged treatment with propranolol
Number of subjects: 100
Study: 29987740

Group type: EXPERIMENTAL
Intervention: Future-oriented text messages
Number of subjects: 270

Group type: COMPARATOR
Intervention: Short-term text messages
Number of subjects: 270
Study: 28545564

Group type: EXPERIMENTAL
Intervention: Sufentanil 1.0 μg ml‐1 plus dexmedetomidine 4 μg ml‐1 (Group SD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil 1.0 μg ml‐1 (Group S)
Number of subjects: 60
Study: 25213114

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-based programme
Number of subjects: 147

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 147
Study: 24376277

Group type: EXPERIMENTAL
Intervention: Behavioral support sessions plus 7 weeks of bupropion therapy (BSS+)
Number of subjects: 1955

Group type: EXPERIMENTAL
Intervention: Behavioral support sessions (BSS)
Number of subjects: 1955

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 1955
Study: 21566568

Group type: EXPERIMENTAL
Intervention: Erythromycin (12.5 mg kg(‐1) per day)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: UDCA (5 mg kg(‐1) every 6 h)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 19687339

Group type: EXPERIMENTAL
Intervention: Exercise intervention (aerobic and strength training, 2.5 hours/week for 1 year)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Exercise intervention (for women who lost more than 2% body fat)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Exercise intervention (for women who lost body fat)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Exercise intervention
Number of subjects: 189
Study: 17449575

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (NaH, 300 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS, 360 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (SSM without GAG)
Number of subjects: 16
Study: 16351336

Group type: EXPERIMENTAL
Intervention: New Hope program to increase parent employment and reduce poverty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New Hope program
Number of subjects: 0
Study: 12154422

Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution (LR)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% hetastarch in normal saline (HS-NS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 6% hetastarch in balanced-saline vehicle (HS-BS)
Number of subjects: 90
Study: 10604523

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Calcium antagonists
Number of subjects: 116

Group type: COMPARATOR
Intervention: Hypertensive group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 116

Group type: COMPARATOR
Intervention: Hypotensive group
Number of subjects: 116
Study: 7605180

Group type: EXPERIMENTAL
Intervention: Underarm braces
Number of subjects: 50

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 50
Study: 2213635

Group type: EXPERIMENTAL
Intervention: Unlimited sleep (11:00 p.m.‐8:00 a.m.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early partial sleep (11:00 p.m.‐3:00 a.m.)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Late partial sleep (4:00 a.m.‐8:00 a.m.)
Number of subjects: 30
Study: 448008

Group type: EXPERIMENTAL
Intervention: Buasch and Lomb Soflens contact lenses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrocurve II contact lenses
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: AOSoftTM hydrophillic contact lenses
Number of subjects: 24
Study: 30063723

Group type: EXPERIMENTAL
Intervention: High VEGF-A protein expression
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: High VEGFR1 expression
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: High VEGFR3 expression
Number of subjects: 585

Group type: EXPERIMENTAL
Intervention: High VEGF-C protein expression
Number of subjects: 585
Study: 27561420

Group type: EXPERIMENTAL
Intervention: Optiscope™
Number of subjects: 168

Group type: COMPARATOR
Intervention: Lightwand
Number of subjects: 168
Study: 24938324

Group type: EXPERIMENTAL
Intervention: Propranolol at 80 mg/day plus HFA-BDP at 100 μg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: HFA-BDP at 400 μg/day
Number of subjects: 16
Study: 22874535

Group type: EXPERIMENTAL
Intervention: Potassium nitrate (614-mg nitrate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (nitrate-free)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrate
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20368057

Group type: EXPERIMENTAL
Intervention: Modified expansive open‐door cervical laminoplasty
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional C3‐C7 cervical expansive open‐door laminoplasty
Number of subjects: 49
Study: 19337557

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs plus rosuvastatin 10 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Rosuvastatin 10 mg alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Omega-3 PUFAs added to rosuvastatin 10 mg
Number of subjects: 30
Study: 16250069

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 14-18 (n = 35)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5 to 7.5 mg/d) in patients with MMSE scores of 23-26 (n = 78)
Number of subjects: 268
Study: 12781159

Group type: EXPERIMENTAL
Intervention: High-protein pre-load (29% protein, approximately 3MJ, 0.5 kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-fat pre-load (40% fat, approximately 3MJ, 0.5 kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-carbohydrate pre-load (60% carbohydrate, approximately 3MJ, 0.5 kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No pre-load
Number of subjects: 16
Study: 10229732

Group type: EXPERIMENTAL
Intervention: GV150526 (800 mg loading dose followed by 400 mg BID maintenance)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: GV150526 (200 mg BID maintenance)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 8916624

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal Therapy (IPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Therapy (CT) and Interpersonal Therapy (IPT)
Number of subjects: 0
Study: 1873610

Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressing
Number of subjects: 65

Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 65
Study: 6871083

Group type: EXPERIMENTAL
Intervention: 50 mg almitrine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 100 mg almitrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 29347888

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioral therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 0
Study: 30115121

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 180
Study: 27181886

Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation via Wei jet nasal airway (Group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Controlled ventilation with improved laryngeal mask airway (Group B)
Number of subjects: 28
Study: 24957863

Group type: EXPERIMENTAL
Intervention: Mosapride 5 mg thrice daily plus Omeprazole 10 mg once daily (GO group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Omeprazole alone (O group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-erosive reflux disease (NERD) patients
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erosive GERD patients
Number of subjects: 60
Study: 22264278

Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS) without additional diagnostic laparoscopy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Primary debulking surgery (PDS) following additional diagnostic laparoscopy
Number of subjects: 200
Study: 19174703

Group type: EXPERIMENTAL
Intervention: American phase 3 diet for 1 month
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Diet plus placebo for 1 month
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg twice a day) plus American phase 3 diet for 2 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Regular diet
Number of subjects: 59
Study: 17438705

Group type: EXPERIMENTAL
Intervention: Experimental treatment (chemotherapy)
Number of subjects: 29
Study: 15975358

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel therapy with intraoperative aprotinin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo for 5 days before surgery and placebo infusions intraoperatively
Number of subjects: 50
Study: 12034155

Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Pulmonary capillary wedge pressure
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Yale Dyspnea-Fatigue Index (YDFI) score
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 6-min walk test
Number of subjects: 201
Study: 9821454

Group type: EXPERIMENTAL
Intervention: Three times weekly ECT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once weekly ECT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High stimulus dose with once weekly ECT
Number of subjects: 0
Study: 7714075

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin (1 mg at 0800, 1000, and 1200 h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 3 mg melatonin
Number of subjects: 16